News for:

 

Click the Chemical Profile link above for detailed information. Visit Betterchem's Drug Index for… Exclusivity Patents and market exclusivity Drug Information Prescribing and other information DMFs Type 2 drug master files Databases Free access to database search 21 CFR FDA regulations for this drug Federal Register FR search results for this drug Drug Recalls For Rx's using this API

FDA Approval Activities for this Drug… Alendronate Sodium Tablets, 35 & 70 mg, Barr, ANDA 76-184 4/23/02 Alendronate Sodium Tablets, 5, 10 & 40 mg, Ivax ANDA 75-711 7/24/02 Alendronate Sodium Tablets, 5, 10, 35, 40 & 70 mg (base), Teva ANDA 75-710 Fosamax (alendronate sodium) Solution, Merck NDA 21-575 9/17/03 9/25/03 9/25/03 Fosamax (alendronate sodium) Tablets, Merck & Co., NDA 20-560/S-037 3/24/03 3/26/03 Fosamax (alendronate sodium) Tablets, Merck & Co., NDA 20-560/S-036 8/5/02 8/12/02 8/5/02 Fosamax (alendronate sodium) Tablets, Merck & Co., NDA 20-560/S-033 8/13/02 8/14/02 Fosamax (alendronate sodium) Tablets, Merck & Co., NDA 20-560/S-031 7/25/02 7/26/02 Fosamax (alendronate sodium) Tablets, Merck & Co., NDA 20-560/S-028 9/16/02 9/20/02 9/17/02 Fosamax Tablets,10mg, Merck Research NDA 20-560/S-012 6/16/99 6/17/99 6/17/99 6/19/00 Fosamax Indication: for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density. Fosamax Tablets, 5mg, 10mg & 40 mg, Merck Research NDA 20-560/S-013 6/8/99 6/19/00 Fosamax (alendronate sodium) Tablets,10mg, Merck Research NDA 20-560/S-018 11/24/99 12/29/99 4/24/03 Fosamax (alendronate sodium) Tablets,10mg, Merck Research NDA 20-560/S-015 11/24/99 12/29/99 4/24/03 Fosamax (alendronate sodium) Tablets,35 & 70mg, Merck Research NDA 20-560/S-021 & S-22 10/20/00 10/30/00 8/16/01 Fosamax Indication: for the prevention (S-021) and treatment (S-022) of postmenopausal osteoporosis, respectively. Fosamax (alendronate sodium) Tablets,10mg, Merck Research NDA 20-560/S-023 9/29/00 10/10/00 Fosamax Indication: Treatment to increase bone mass in men with osteoporosis. Fosamax (alendronate sodium) Tablets,70mg, Merck & Co., NDA 20-560/S-024 & S-025 1/31/01 2/8/01 2/8/01 Fosamax (alendronate sodium) Tablets, Merck & Co., NDA 20-560/S40 9/17/03 9/29/03 Fosamax Indication: Treatment to increase bone mass in men with osteoporosis. Alendronate Sodium Tablets, Mylan Pharmaceuticals, Fosamax (alendronate sodium) Tablets & Oral Solution, Merck Fosamax (alendronate sodium) Tablets & Oral Solution, Merck Fosamax (alendronate sodium) Tablets & Oral Solution, Merck Alendronate Sodium Tablets, Watson Laboratories | Fosamax Plus D (alendronate sodium vitamin D3) Tablets, Merck & Co., Approval | Fosamax (alendronate sodium) Tablets, Merck & Co., Labeling Revision | Fosamax (alendronate sodium) Oral Solution, Merck & Co., Labeling Revision | Fosamax Plus D (alendronate sodium Vitamin D3) Tablets, Merck & Co., Labeling Revsion | Fosamax (alendronate sodium) Tablets, Merck & Co., New or Modified Indication | Fosamax (alendronate sodium) Oral Solution, Merck & Co., Labeling Revision | Fosamax (alendronate sodium) Tablets, Merck & Co., Labeling Revision | Fosamax Plus D (alendronate sodium I.U. Vitamin D) Tablets, Merck & Co., Labeling Revision Visit Betterchem's Drug Index for FDA's latest approval information.   Find other drugs… A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | News Feed for each API | USActives.com | Pharma Job Search | Pharma Company News © 2011 FindingHealthOnline™